Virpax Pharmaceuticals VRPX
$ 0.58
-1.19%
Quarterly report 2024-Q3
added 11-14-2024
Virpax Pharmaceuticals Balance Sheet 2011-2024 | VRPX
Annual Balance Sheet Virpax Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | 489 K | 1.22 M | 452 K | - | - | - | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
7.69 M | 3.09 M | 2.09 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
7.69 M | 3.09 M | 2.09 M | 1.02 M | 2.78 M | 1.25 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-59.5 M | -44.4 M | -22.7 M | - | -6.31 M | -3 M | - | - | - | - | - | - | - |
Total Assets |
9.63 M | 19.7 M | 39.6 M | 465 K | 46.7 K | 61.5 K | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
9.14 M | 19 M | 36.8 M | 54.8 K | - | - | - | - | - | - | - | - | - |
Book Value |
1.93 M | 16.6 M | 37.5 M | -556 K | -2.73 M | -1.19 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.93 M | 16.6 M | 37.5 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Virpax Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | 1.07 M | 1.07 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | 1.02 M | 1.02 M | 1.02 M | - | 1.02 M | 1.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.36 M | 5.39 M | 4.34 M | 7.69 M | 6.53 M | 3.65 M | 3.29 M | 3.09 M | 4.21 M | 2.48 M | 2.19 M | 2.09 M | 1.81 M | 3.85 M | 3.66 M | 4.68 M | 4.68 M | 4.68 M | 4.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-68.2 M | -66.2 M | -62.8 M | -59.5 M | -55 M | -49 M | -45.9 M | -44.4 M | -41.4 M | -33.7 M | -27.8 M | -22.7 M | -18.6 M | -15.4 M | -13 M | -10.6 M | -10.6 M | -10.6 M | -10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
304 K | 2.59 M | 3.13 M | 9.63 M | 13 M | 16 M | 18.5 M | 19.7 M | 23.6 M | 29.4 M | 34.7 M | 39.6 M | 43.3 M | 11.4 M | 13.2 M | 465 K | 465 K | 465 K | 465 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
17.2 K | 1.87 M | 1.87 M | 9.14 M | 12.2 M | 14.8 M | 17 M | 19 M | 20.6 M | 26.1 M | 30.8 M | 36.8 M | 41.7 M | 10.5 M | 12.3 M | 54.8 K | 257 K | 54.8 K | 54.8 K | 41.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-2.05 M | -2.79 M | -1.21 M | 1.93 M | 6.51 M | 12.3 M | 15.2 M | 16.6 M | 19.4 M | 26.9 M | 32.6 M | 37.5 M | 41.5 M | 7.54 M | 9.56 M | -4.22 M | -4.22 M | -4.22 M | -4.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-2.05 M | -2.79 M | -1.21 M | 1.93 M | 6.51 M | 12.3 M | 15.2 M | 16.6 M | 19.4 M | 26.9 M | 32.6 M | 37.5 M | 41.5 M | 7.54 M | 9.56 M | -4.22 M | -4.22 M | -4.22 M | -4.22 M | -2.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency